Lead researcher Professor Nakajima discovered the Rheumatoid Arthritis (RA) biomarker and therapeutic target Synoviolin/Hrd1, a ubiquitin E3 ligase overexpressed in RA patients.
As per the terms of the deal, Progenra will work with Professor Nakajima to bring existing inhibitors to market and utilize Progenra’s UbiPro Drug Discovery Platform to identify additional inhibitors.
Progenra president Tauseef Butt said the collaboration will bring to market a novel treatment for patients suffering from Rheumatoid Arthritis.